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Abstract
Context Although consensus guidelines recommend dopamine agonists (DAs) as the first-line approach in prolactinomas, 
some patients may opt instead for upfront surgery, with the goal of minimizing the need for continuation of DAs over the 
long term. While this approach can be recommended in selected patients with a microprolactinoma, the indication for upfront 
surgery in macroprolactinomas remains controversial, with limited long-term data in large cohorts. We aimed at elucidating 
whether first-line surgery is equally safe and effective for patients with micro- or macroprolactinomas not extending beyond 
the median carotid line (i.e., Knosp grade ≤ 1).
Methodology Retrospective study of patients with prolactinomas Knosp grade ≤ 1 treated with upfront surgery. The primary 
endpoint was patients’ dependence on DAs at last follow-up. The secondary endpoint was postoperative complications. 
Independent risk factors for long-term dependence on DAs were analyzed.
Results A microadenoma was noted in 45 patients (52%) and a macroadenoma in 41 (48%), with 17 (20%) harboring a Knosp 
grade 1 prolactinoma. Median follow-up was 80 months. First-line surgery resulted in long-term remission in 31 patients 
(72%) with a microprolactinoma and in 18 patients (45%) with a macroprolactinoma (p = 0.02). DA therapy was ultimately 
required in 11 patients (24%) with microadenomas vs. 20 (49%) with macroadenomas (p = 0.03). As for the latter, DA was 
required in 13 patients (76%) with Knosp grade 1 macroadenomas vs. 7 patients (29%) with Knosp grade 0 macroadenomas 
(p = 0.004). There was no mortality, and morbidity was minimal. Knosp grade 1 prolactinomas (OR 7.3, 95% CI 1.4–37.7, 
p = 0.02) but not adenoma size (i.e., macroprolactinomas) were an independent predictor of long-term dependence on DAs.
Conclusions First-line surgery in patients with microprolactinomas or macroprolactinomas Knosp grade 0 resulted in a good 
chance of non-dependency on DA therapy. However, in patients with prolactinomas Knosp grade 1, first-line surgery cannot 
be recommended, as adjuvant DA therapy after surgery is required in the majority of them over the long term.
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Abbreviations
DA  Dopamine agonist
MRI  Magnetic resonance imaging
PRL  Prolactin
TSS  Transsphenoidal surgery
Introduction
While consensus guidelines recommend dopamine agonists 
(DAs) as the first-line approach in the treatment of prol-
actinomas, [1–4] surgery is primarily indicated in patients 
who are resistant to or intolerant of DAs, in cases of cystic 
adenomas, or intratumoral hemorrhage with persisting visual 
disturbances [5–11]. Thus, most surgical series report the 
results of a second-line approach in patients with evidence 
of resistance or intolerance to DAs [5, 12].
In 2006, the Pituitary Society revised its guidelines to 
include surgery in dedicated centers with experienced sur-
geons as a possible first-line approach for prolactinomas 
when it is the patient’s preference, rather than long-term 
DA therapy [13]. This approach has increasingly emerged 
given that DAs are required over the long-term in up to 80% 
of patients. [14] DAs have been associated with side effects 
such as nausea, dizziness, and postural hypotension; how-
ever, they are present in only a minority of patients [15]. 
Although side effects of cabergoline were recorded in 68% 
of women in a large cohort with hyperprolactinemic amen-
orrhea, only 3% of them ultimately had to discontinue drug 
therapy due to intolerance.[16] Also, cabergoline-associ-
ated valvulopathy is uncommon, [17, 18] and its clinical 
significance remains unclear [19]. In a recent cohort study, 
no association was reported between a clinically significant 
valvulopathy and low-dose cabergoline therapy [20]. On rare 
occasions, personality changes associated with DAs have 
been reported, including gambling, hypersexuality and com-
pulsive shopping [21–23]. It is possible that patients don’t 
mention these effects due to feelings of shame, with potential 
detrimental psychosocial consequences [24]. Importantly, 
though, the low prevalence of these side effects should not 
cast doubt on the well-defined medical treatment approach to 
prolactinomas [25, 26]. The renewed acceptance of surgical 
treatment of prolactinomas, however, primarily applies to 
patients with a microprolactinoma, in whom a short-term 
cure rate of about 90% can be anticipated [27–31]. However, 
the indication for upfront surgery in macroprolactinomas 
remains controversial, and long-term data on patients in 
large cohorts is limited [8, 32–34].
Our purpose was to elucidate whether first-line surgery 
is equally safe and effective for patients with microprol-
actinomas or macroprolactinomas not extending beyond 
the median carotid line (Knosp grade ≤ 1). In particular, 
we aimed at investigating whether tumor characteristics at 
diagnosis have an impact on the control of hyperprolactine-
mia and long-term dependence on DAs.
Patients and methods
Study design
We conducted a retrospective study reviewing data from 
prolactinoma patients stored in our institutional database. 
The records were prospectively maintained from January 
1996 to December 2015. All consecutive patients in whom 
first-line surgery was performed for the treatment of either 
micro- or macroprolactinomas were analyzed. The Human 
Research Ethics Committee of Bern (Kantonale Ethikkom-
mission KEK Bern, Bern, Switzerland) approved the project 
(KEK n° 10-10-2006 and 8-11-2006).
Preoperative assessment
Diagnosis was based on preoperative clinical and biochemi-
cal assessment as well as a standard protocol for pituitary 
magnetic resonance imaging (MRI; see below). Types of 
DA-agonist therapy and maximal doses were noted (e.g., 
bromocriptine, quinagolide, cabergoline).
Clinical assessment
Baseline characteristics included patients’ age, sex, body 
mass index (BMI), and clinical reason for presentation (i.e., 
headache, visual deficits).
Biochemical assessment
PRL levels, including the immunoradiometric PRL assay 
(IRMA), which uses serum dilution to overcome the high-
dose PRL hook effect, [35] were assessed. The presence of 
macroprolactin was routinely assessed [36]. Upper limits 
of PRL levels were 20 ng/mL [37]. As for pituitary axis 
deficits, partial hypopituitarism was defined as impaired 
secretion of one or more pituitary hormones. Secondary 
adrenal insufficiency was characterized by the presence of 
low cortisol (< 50 nmol/L) levels in the serum, or normal 
cortisol but inadequate responses to the adrenocorticotropin 
(ACTH) stimulation test or insulin tolerance test. The diag-
nosis of secondary hypothyroidism was based on a finding of 
low-normal thyroid-stimulating hormone (TSH) levels and 
low free thyroxin (FT4) level. A gonadotropin deficiency or 
central hypogonadism was considered in the case of low-
normal levels of gonadotropins in parallel with low estra-
diol/testosterone levels.
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MRI evaluation
MRI was performed on a 1.5- or 3-T system including a 
Proton/T2-weighted whole-brain study with unenhanced, 
contrast-enhanced, dynamic contrast-enhanced and post 
contrast-enhanced overlapping studies in the axial, sagittal 
and coronal planes over the sellar region [38, 39]. A tumor 
with a diameter of 1–10 mm was defined as a microadenoma 
and > 10 mm as a macroadenoma. Knosp classification was 
used to describe invasiveness of the cavernous sinus [40, 
41]. The gold standard for diagnosis was immunohistochem-
ical confirmation with a PRL antibody as an immunohis-
tochemical marker according to the WHO classification of 
neuroendocrine tumors [42].
Indication for surgery
For all patients, the indication for surgery was discussed 
at an interdisciplinary pituitary tumor board meeting, with 
consensus tailored to preventing patients from becoming 
dependent on DA therapy over the long term. The indi-
cation for upfront surgery was further discussed with the 
patient and based on patients’ preference for surgical treat-
ment rather than long-term DA therapy. Surgery was consid-
ered both for microprolactinomas and macroprolactinomas 
not extending beyond the medial carotid line (i.e., Knosp 
grade ≤ 1). Because health insurance in Switzerland cov-
ers both medical and surgical therapy of all its residents, 
treatment decisions are not based on financial considera-
tions [43].
Pituitary surgery was performed by three experienced 
neurosurgeons (RWS, LM, JB) using a transseptal, transs-
phenoidal microsurgical approach with sellar reconstruction, 
as previously described [44].
Inclusion and exclusion criteria
A flow chart of the patient selection process is depicted 
in Fig. 1. Patients who had previously received DAs were 
excluded from the study (n = 78). Patients with cavernous 
sinus infiltration (i.e., Knosp grade ≥ 2) were not considered 
for a primary surgical approach (n = 6). Furthermore, twelve 
patients were excluded from this study given the missing 
baseline MRI data for classification as a microadenoma or a 
macroadenoma (n = 3), and the missing data on their long-
term follow-up (n = 9).
Postoperative and long‑term assessment
Early follow-up took place three months after pituitary sur-
gery. In patients with elevated PRL levels (> 20 µg/L) at 
three months, DA therapy was initiated (e.g., bromocriptine, 
quinagolide, and mainly cabergoline) [45] In patients with 
marginally increased prolactin levels above the normal range 
but lacking clinical symptoms, DA therapy was not initiated, 
and prolactin levels were controlled during routine follow-
up. Late follow-up was defined as the last documented visit 
Fig. 1  Flow chart of patient 
selection process. Out of 182 
patients with a prolactinoma, 
first-line surgery was performed 
in 98 patients, with 86 patients 
included in the final analysis 
given the presence of long-term 
follow-up data
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to the endocrine outpatient clinic of the Bern University 
Hospital. DAs were tapered 24 months after initiation of 
medical therapy if PRL levels had normalized [46, 47]. 
There was no routine follow-up to control the tumor size by 
means of sellar MRI.[48, 49] Patients were considered to 
be in remission if the PRL level was < 20 µg/L at follow-up.
Statistical analyses
Data were analyzed using IBM SPSS statistical software 
Version 24.0 (IBM Corp., New York, NY, USA) and 
GraphPad Prism (V7.04 software, San Diego, CA, USA). 
Continuous variables were examined for homogeneity of 
variance and are expressed as mean ± SD unless otherwise 
noted. Serum PRL levels are presented as median values 
and interquartile range (IQR, 25th to 75th percentile). Cat-
egorical variables are given as numbers and percentages. For 
comparisons of means between groups (i.e., patients with 
micro- and macroadenomas), Student’s t-test was used for 
normally distributed data, and the Mann–Whitney test for 
nonparametric data. The Wilcoxon signed-rank test was used 
to evaluate paired differences in PRL levels before and after 
treatment. Categorical variables were compared using Pear-
son’s chi-square test or Fisher’s exact test, as appropriate. 
The Kaplan–Meier method was used to analyze recurrence-
free intervals during follow-up, and the significance was cal-
culated using the log-rank (Mantel–Cox) test. Odds ratios 
(ORs) and 95% confidence intervals (CIs) of independent 
factors for early negative outcome (i.e. postoperative PRL 
levels > 20 μg/L) were analyzed by univariable and multi-
variable logistic regression. We assessed the proportion of 
patients with long-term dependence on DAs and performed 
time-dependent multivariable regression analysis to calcu-
late hazard ratios (HR) for potential risk factors. The vari-
ables tested were: age at diagnosis, sex, headache at pres-
entation, hypopituitarism at diagnosis, BMI (kg/m2), initial 
PRL levels, adenoma size, and Knosp classification. The 
multivariable regression analysis included all dependent risk 
factors in the univariable regression with a p value ≤ 0.05. 
Baseline PRL values were log transformed before being 
imputed in the regression analysis, as data showed a posi-
tively skewed distribution. Significance level was set at 5%.
Results
Baseline characteristics
Patients’ characteristics at diagnosis are summarized in 
Table 1. Eighty-six patients (15 men, 71 women) met the 
inclusion criteria. A microadenoma was noted in 45 patients 
(52%) and a macroadenoma in 41 (48%). The prevalence 
of microprolactinomas was not significantly greater in 
women than in men (56% vs. 33%, p = 0.16). There was a 
non-significant tendency towards lower age, lower BMI, and 
lower prevalence of headache in patients with microadeno-
mas compared to patients with macroadenomas. Patients 
with microadenomas had significantly lower PRL levels 
than those with macroadenomas. There was a statistically 
non-significant tendency for an increased prevalence of gon-
adotrophic, thyrotrophic and corticotrophic insufficiency in 
macroadenomas compared to microadenomas. Prolactinoma 
extension to the medial carotid line (i.e., Knosp grade 1) 
was not noted in any patients with a microprolactinoma, and 
in 17 patients (41%) with macroprolactinomas (p < 0.001).
Early postoperative remission rates
Immunohistological staining confirmed a prolactinoma 
in all patients. Serum PRL values decreased significantly 
in both cohorts, from 130  μg/L (IQR 68–197  μg/L) to 
12 μg/L (IQR 6–28 μg/L), p < 0.001, in microadenomas 
and from 303 μg/L (IQR 207–1100 μg/L) to 28 μg/L (IQR 
9–114 μg/L), p = 0.01, in macroadenomas (Fig. 2). Postop-
erative PRL values remained significantly higher in patients 
with macroprolactinomas than in those with microprolacti-
nomas (p = 0.03). Postoperative normalization of PRL lev-
els was obtained in 32 patients (76%) with microadenomas 
and in 18 patients (53%) with macroadenomas (p = 0.05). 
Among the subgroup of patients with macroprolactinomas 
only, remission was noted in 14 (74%) of them with a Knosp 
grade 0 prolactinoma, and in 4 (27%) with a Knosp grade 1 
prolactinoma (p = 0.01).
Univariable analysis revealed that male sex, high preop-
erative PRL levels, Knosp grading (i.e., Knosp grade 1), 
and tumor size (i.e., macroadenoma) were related to early 
negative surgical results (i.e., PRL levels > 20 μg/L). No sig-
nificant risk factors for early negative outcome were noted 
in the multivariable analysis (Table 2).
Long‑term remission rates
i) Surgery alone
Remission was achieved with surgery alone in 49 patients 
(59%), including 31 (72%) with a microprolactinoma and 18 
(45%) with a macroprolactinoma (p = 0.02). With regard to 
macroprolactinomas only, surgery alone resulted in long-
term remission in 15 patients (65%) with a Knosp grade 0 
prolactinoma, compared to 3 patients (18%) with a Knosp 
grade 1 prolactinoma (p = 0.004). Thereby, recurrence-
free intervals were not significantly longer in patients with 
a microadenoma (354 ± 29.7 months) than in those with 
a macroadenoma (339.3 ± 43.7  months); log-rank test, 
p = 0.50. However, the recurrence-free intervals were sig-
nificantly shorter in patients with a Knosp grade 1 adenoma 
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(110.5 ± 32.2 months) than in those with a Knosp grade 0 
adenoma (365.4 ± 22.9 months; log-rank test, p < 0.001).
ii) Multimodal treatment
Long-term remission was attained in 76 patients (92%) 
with multimodal treatment (i.e., surgery ± DA), namely 
in 41 patients (95%) with a microprolactinoma vs. 35 
patients (88%) with a macroprolactinoma; p = 0.25; 
Fig.  3). Thereby, recurrence-free intervals were not 
significantly shorter in patients with a microadenoma 
(354.3 ± 25.6 months) than in those with a macroadenoma 
(324.4 ± 33.2 months); log-rank test, p = 0.34 (Fig. 4a). 
However, the recurrence-free intervals were significantly 
shorter in patients with a Knosp grade 1 prolactinoma 
(201.5 ± 25.2 months) than in those with Knosp grade 0 
prolactinoma (396.4 ± 22.5 months; log-rank test, p = 0.01; 
Fig. 4b). With regard to macroprolactinomas only, mul-
timodal treatment resulted in long-term remission in 22 
patients (96%) with a Knosp grade 0 adenoma vs. 13 
patients (76%) with a Knosp grade 1 adenoma (p = 0.14; 
Fig. 3).
Long‑term dependence on DAs
For the long-term control of hyperprolactinemia, a signifi-
cantly greater need for persistent DA therapy was noted in 
20 patients (49%) with a macroprolactinoma compared to 
11 patients (24%) with a microprolactinoma (p = 0.03). In 
particular, as for macroprolactinomas, DA was required 
in 13 patients (76%) with Knosp grade 1 macroadenomas 
compared to 7 patients (29%) with Knosp grade 0 mac-
roadenomas (p = 0.004; Fig. 3). Specifically, DAs were 
required in 11 patients (24%) with microadenomas, i.e. 
bromocriptine in 3 (6%) and cabergoline in 8 patients 
(18%), compared to 20 (49%) patients with a macroad-
enoma (i.e., bromocriptine in 8 (20%), and cabergoline 
in 12 (29%) patients (p = 0.03). Of the 31 (36%) patients 
receiving DAs at last follow-up, 11 (13%) patients received 
bromocriptine, and 20 (23%) patients received caber-
goline. Daily doses at last follow-up were 5.0 ± 2.6 mg 
for bromocriptine, 61.4 ± 19.3 µg for quinagolide, and 
0.53 ± 0.21 mg for cabergoline Table 3).
The risk factors for long-term DA dependence are 
summarized in Table 4. Significant risk factors in the 
univariable analysis included male sex and Knosp grade 
1 prolactinomas. Multivariable Cox regression analyses 
revealed Knosp grading but not adenoma size (i.e., mac-
roadenoma) as an independent risk factor for dependence 
on DAs. Eight patients (9%) successfully quit DA therapy 
during a median follow-up of 140 months.
Fig. 2  Impact of first-line surgery on PRL levels as a function of ade-
noma size. Differences in PRL levels before and after surgery in rela-
tion to adenoma size. Both baseline and postoperative PRL levels are 
significantly higher in patients with macroprolactinomas than those 
with microprolactinomas (p = 0.01 and p = 0.04, respectively), but not 
at long-term follow-up (p = 0.39). PRL levels significantly decreased 
in both cohorts compared to baseline, independent of the initial tumor 
size (i.e., microadenoma or macroadenoma). There is a significant 
difference between postoperative and long-term PRL values (p = 0.01 
for microadenomas; p = 0.03 for macroadenomas, respectively). 
(***p < 0.001; **p < 0.01; *p < 0.05)
Table 2  Predictors of early 
negative outcome (postoperative 
PRL levels > 20 μg/L)
BMI body mass index, CI confidence intervals, DA dopamine agonist, OR odds ratio, PRL prolactin
Predictive factors Univariable analyses 
OR (95% CI)
P value Multivariable analy-
ses OR (95% CI)
P value
Age (years) 1.0 (1.0–1.1) 0.71
Sex (male) 6.1 (1.7–22.4) 0.01 2.3 (0.4–15.0) 0.39
Headache (baseline) 1.0 (0.3–3.1) 0.99
Hypopituitarism (baseline) 0.7 (0.2–1.9) 0.45
Baseline BMI (kg/m2) 1.0 (0.9–1.1) 0.70
PRL levels (baseline) 13.0 (3.2–52.5)  < 0.001 11.1 (2.1–59.4) 0.05
Knosp grading (Knosp grade 1) 8.4 (2.3–30.5) 0.001 3.3 (0.6–19.0) 0.17
Adenoma size (Macroadenoma) 2.8 (1.1–7.6) 0.04 1.8 (0.4–8.0) 0.41
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Characteristics at last follow‑up
Patients’ characteristics at last follow-up are summarized 
in Table 3. The median follow-up period was 80 (13–408) 
months and did not differ between the two cohorts. Baseline 
PRL levels were significantly higher in patients with long-
term dependence on DAs than in those without; 284 µg/L 
(IQR 200–1000 µg/L) vs. 136 µg/L (IQR 75–234 µg/L), 
p = 0.04. 
i) Surgery alone
Compared to postoperative values, PRL levels remained 
stable both in the microadenoma and the macroadenoma 
cohorts, namely from 12 µg/L (IQR 7–20 µg/L) to 7 μg/L 
(IQR 5–14 μg/L), p = 0.99 (microadenoma cohort), and from 
15 µg/L (IQR 10–22 µg/L) to 12 μg/L (IQR 7–45 μg/L), 
p = 0.13, in the macroadenoma cohort, respectively. At last 
follow-up, serum PRL levels in patients with a microad-
enoma were not significantly different from those in patients 
with a macroadenoma (p = 0.41). Likewise, PRL levels were 
not significantly different in patients with Knosp grade 1 
prolactinomas compared to those with Knosp grade 0 prol-
actinomas (p = 0.25). The number of patients with headache 
dropped from 11 (20%) to 2 (4%) (p = 0.01), both in patients 
with microprolactinomas, though not significantly (12% vs. 
3%, p = 0.19) and in patients with macroprolactinomas (33% 
vs. 5%, p = 0.05). There was a significant decrease in the 
prevalence of hypogonadism (p < 0.001), both in patients 
with microprolactinomas (71% vs. 10%, p < 0.001) and 
macroprolactinomas (92% vs. 25%, p = 0.003), with no 
significant difference in the prevalence of hypogonadism 
at long-term follow-up between the two cohorts (p = 0.55). 
At the final follow-up, gonadotropic, thyrotropic and 
Fig. 3  Long-term outcome following first-line surgery. Multimodal 
treatment (i.e., surgery ± DA) resulted in long-term control of hyper-
prolactinemia in 41 patients (95%) with a microprolactinoma vs. 35 
patients (88%) with a macroprolactinoma (p = 0.25), namely in 22 
macroadenomas (96%) of Knosp grade 0 vs. 13 (76%) with Knosp 
grade 1 (p = 0.14). Surgery alone resulted in long-term remission in 
31 patients (72%) with a microprolactinoma vs. 18 patients (45%) 
with a macroprolactinoma (p = 0.02); namely in 15 (68%) patients 
with a macroadenoma Knosp grade 0 vs. 3 (18%) patients with a 
macroadenoma Knosp grade 1 (p = 0.004). For the long-term con-
trol of hyperprolactinemia, a significantly greater need for DA ther-
apy was noted in patients with a macroprolactinomas (49%) than in 
patients with a microprolactinomas (24%, p = 0.03), and in macropro-
lactinomas Knosp grade 1 (76%) compared to macroprolactinomas 
Knosp grade 0 (29%, p = 0.004) (**p < 0.01; *p < 0.05)
Fig. 4  Kaplan–Meier estimation of recurrence-free intervals. a 
Recurrence-free intervals were not significantly shorter in patients 
with a microadenoma (354.3 ± 25.6  months) than in those with a 
macroadenoma (324.4 ± 33.2 months); log-rank test, p = 0.34. b How-
ever, recurrence-free intervals were significantly shorter in patients 
with a Knosp grade I prolactinoma (201.5 ± 25.2  months) than in 
those with a Knosp grade 0 prolactinoma (396.4 ± 22.5 months; log-
rank test, p = 0.01)
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corticotropic insufficiency were not significantly different 
between the two groups.
ii) Multimodal treatment
Compared to postoperative values, PRL levels remained sta-
ble in the microadenoma cohort and decreased in the mac-
roadenoma cohort, namely from 12 μg/L (IQR 6–28 μg/L) to 
12 µg/L (IQR 7–21 µg/L), p = 0.20 (microadenoma cohort), 
and from 28  μg/L (IQR 9–114  μg/L) to 14  µg/L (IQR 
8–20 µg/L), p = 0.03, in the macroadenoma cohort, respec-
tively. At last follow-up, serum PRL levels in patients with 
microadenomas were not significantly different from those in 
patients with macroadenomas (Fig. 2). Likewise, PRL levels 
were not significantly different in patients with Knosp grade 
1 prolactinomas compared to those with Knosp grade 0 pro-
lactinomas (p = 0.24). The number of patients with headache 
dropped from 18 (22%) to 2 (2%) (p < 0.001), which was 
significant both in patients with a macroprolactinoma (29% 
vs. 2%, p = 0.001) and a microprolactinoma (16% vs. 2%, 
p = 0.03). There was a significant decrease in the prevalence 
of hypogonadism, both in patients with microprolactinomas 
(93% vs. 19%, p < 0.001) and macroprolactinomas (88% vs. 
38%, p = 0.001), with no significant difference in the preva-
lence of hypogonadism between the two cohorts over the 
long term. At last follow-up, gonadotropic, thyrotropic and 
corticotropic insufficiency were not significantly different 
between the two groups.
Morbidity and mortality
There was no mortality in patients with a microadenoma 
or a macroadenoma. Surgical complications consisted of 
transient rhinoliquorrhea (3%) requiring transsphenoidal 
revision by autologous fat graft and dural patching in two 
patients following surgery on a Knosp grade 1 macroprol-
actinoma. Transient syndrome of inappropriate secretion of 
antidiuretic hormone (10%) and diabetes insipidus (13%), 
as well as slight upper bitemporal quadrantal hemianopsia, 
was seen in one patient. We noted no vascular injuries, men-
ingitis or abscesses.
Compared to baseline, new thyrotrophic insufficiency 
after surgery was noted in 6 patients (7%), with 5 (6%) 
Table 3  Patient characteristics 
at last follow-up
BMI body mass index, n numbers, SD standard deviation, IQR interquartile range
Characteristics at last follow-up Microadenoma Macroadenoma Total P value
Follow-up time in months (median, range) 79 (13–396) 97 (13–408) 80 (13–408) 0.3
BMI (kg/m2 ± SD) 24.7 ± 5.7 27.7 ± 5.0 26.1 ± 5.6 0.02
Headache, n (%) 1 (2) 1 (2) 2 (2) 0.99
Affected pituitary axes, n (%)
 Gonadotropin deficiency 5 (19) 8 (38) 13 (27) 0.19
 Secondary hypothyroidism 2 (5) 6 (15) 8 (9) 0.15
 Secondary adrenal insufficiency 0 (0) 3 (8) 3 (4) 0.1
Prolactin levels in μg/L (median; IQR) 11.9 (7.3–21.0) 13.8 (8.2–20.4) 12.7 (7.5–20.9) 0.29
Prolactin levels normalized
 Multimodal treatment 41 (95) 35 (88) 76 (92) 0.25
 Surgery alone 31 (72) 18 (45) 49 (59) 0.02
Dopamine agonists required 11 (24) 20 (49) 31 (36) 0.03
Table 4  Predictors of long-
term dependence on dopamine 
agonists
BMI body mass index, CI confidence intervals, DA dopamine agonist, HR hazard ratio, PRL prolactin




P value Multivariable analyses
HR (95% CI)
P value
Age (years) 1.0 (1.0–1.0) 0.65
Sex (male) 2.6 (1.2–5.9) 0.02 1.5 (0.6–4.2) 0.39
Headache (baseline) 2.2 (0.9–5.3) 0.07
Hypopituitarism (baseline) 0.6 (0.3–1.5) 0.29
Baseline BMI (kg/m2) 1.0 (0.9–1.1) 0.45
PRL levels (baseline) 1.6 (0.9–3.0) 0.10
Knosp grading (Knosp grade 1) 2.7 (1.3–5.6) 0.01 2.2 (1.0–5.4) 0.03
Adenoma size (Macroadenoma) 1.5 (0.7–3.2) 0.28
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harboring a macroprolactinoma. New corticotrophic insuf-
ficiency was noted in 2 patients (2%), with 1 patient (1%) 
harboring a macroprolactinoma.
Discussion
The present analysis of the largest series reported to date 
with a surgery-first approach reveals that over the long term 
(7 years) (i) upfront surgery resulted in a high likelihood of 
avoiding DA therapy in patients with microprolactinomas; 
(ii) persistent hyperprolactinemia and the need for adju-
vant DA therapy is significantly greater in patients with a 
macroprolactinoma, especially in those with a Knosp grade 
1 adenoma; and (iii) no significant short-term or long-term 
morbidity or mortality could be documented.
TSS and DA represent effective treatment options for pro-
lactinomas [50]. However, long-term treatment with DAs 
is often required, and can lead to potential adverse effects, 
in particular the recently documented personality changes 
associated with DAs, [24] lack of compliance, and limited 
convenience for patients [21, 27, 51].
In recent years, the scale of indications has tipped towards 
TSS due to its favorable outcome and the potential adverse 
effects of DAs over the long term [52]. This approach is 
reinforced by two recent meta-analyses confirming that dis-
ease remission can be achieved with surgery in the majority 
of patients [7, 8]. As a result, choosing to perform surgi-
cal treatment as a first-line approach might be beneficial 
given the potential for adenoma fibrosis associated with DA 
therapy. Fibrosis has been shown to hamper outcome, [53, 
54] but results remain controversial [5]. Consequently, the 
PRolaCT trial started recruiting participants with the goal 
of investigating whether TSS for microprolactinoma and 
macroprolactinoma resection is superior to standard care 
as a first-line approach or a second-line treatment (NCT 
04,107,480).
As for macroprolactinomas, they often present with 
higher prolactin levels and a tendency to extend to the cav-
ernous sinus, as documented in the current study with 41% 
of patients with a Knosp grade 1 macroadenoma. Conse-
quently, upfront surgery did not result in long-term remis-
sion in a substantial number of patients, and there was a need 
for long-term DA therapy after surgery in about half of them. 
Likewise, Donegan et al. reported persistent dependence 
on DAs in 66% of their patients [55]. The slightly higher 
need for continuing DA therapy might be due to their inclu-
sion of patients with prior DA therapy (in contrast to the 
present study) in whom perivascular tumor fibrosis may 
hamper complete adenoma resection, as mentioned above 
[53, 54, 56]. All the same, although recurrence-free inter-
vals did not differ significantly with regard to adenoma size, 
patients with adenoma infiltration had significantly shorter 
recurrence-free intervals than those without. It is conceiv-
able that the smaller sample size of patients with macroad-
enomas conceals a true effect [57].
Considering these factors, the current study indicates that 
a surgery-first approach should not be considered in patients 
with macroprolactinomas.
Invasive macroprolactinomas in particular represent a 
therapeutic challenge. We noted that surgery alone resulted 
in long-term remission in 65% of patients with Knosp grade 
0 macroadenomas, as opposed to only 18% with Knosp grade 
1 adenomas (p = 0.004). In keeping with the finding that 
the Knosp grading was an independent predictor of long-
term dependence on DAs, upfront surgery cannot be rec-
ommended in patients with a Knosp grade 1 prolactinoma.
Pituitary tumors in general have a considerable impact 
on patients’ functional status [58]. Thus, quality of life is 
impaired over the long-term in many patients with pitui-
tary adenomas compared to the general population [59, 
60]. Recently, it has been demonstrated that healthcare 
utilization and costs of patients treated for a prolactinoma 
are mainly associated with health-related quality of life.
[61] Interestingly, tumor size and prolactinoma treatment 
were however not significantly associated with healthcare 
utilization [61]. In addition, treatment costs were not sig-
nificantly higher for patients with a macroprolactinoma, 
except in terms of medication costs [61]. With regard to 
the treatment strategy being chosen, transsphenoidal sur-
gical resection of microprolactinomas has been shown to 
be more cost-effective than life-long medical therapy in 
young patients with a life expectancy greater than 10 years 
[62]. However, these results require that surgery be per-
formed at high-volume centers by experienced pituitary 
surgeons with low complication rates. Therefore, depend-
ence on DAs in some patients with a macroprolactinoma 
should also be considered in relation to the potential risks 
of surgery. Although morbidity, mortality and rates of new 
endocrinopathies (3% and 0%, and 5%, respectively) in our 
study are in line with previous findings, [63] they are not 
nonexistent. In contrast, DAs can be easily administered 
and monitored and are usually well tolerated. In addition, 
they have well-known anti-secretory and anti-proliferative 
effects [64]. With regard to the low need for persistent DAs 
over the long term in our cohort of patients with first-line 
surgery—in particular those with microprolactinomas—
indiscriminate prescription of DAs at diagnosis without 
the support of interdisciplinary consensus findings or care-
ful evaluation by MRI cannot be advised. Even if side 
effects are only infrequently encountered, they can still 
have severe psychosocial implications including debt, in 
particular in the case of DA-induced personality changes 
(gambling, hypersexuality, compulsive shopping), [21, 24] 
which are usually not immediately reported by patients 
as they feel intense shame. Although DA’s have not been 
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reported to induce systemic fibrosis at low doses, [65–67] 
Ono and colleagues reported that up to 18% of patients 
needed persistent high-dose cabergoline treatment to nor-
malize hyperprolactinemia, irrespective of tumor size [68]. 
In this regard, cumulative doses of DA might account for 
long-term adverse effects, [23, 69, 70] and new concerns 
about long-term safety of DAs have emerged over time [21, 
23, 24, 52]. Of note, in contrast to initial studies reporting 
that many patients treated with cabergoline remained in 
remission after drug withdrawal, [47] later reports have 
described early recurrence of hyperprolactinemia follow-
ing discontinuation of DAs, particularly in patients with 
macroprolactinomas [71–73]. These results are in line with 
a recent meta-analysis showing that long-term remission 
was lower after DA withdrawal (34%) than after transsphe-
noidal surgery (64%), [8] while a previous meta-analysis 
reported even lower (21%) long-term remission rates after 
DA withdrawal [14].
Study limitations
Follow-up at < 24 months in a few patients may have inter-
fered with the results of long-term dependence on DAs, 
as our treatment regime consisted of tapering medications 
24 months after initiation of the medical therapy if PRL 
levels had normalized and/or adenoma reduction of > 50% 
was attained. Because follow-up continued for such a long 
time, data on pituitary insufficiency was missing for some 
patients. This included gonadotrophic insufficiency in 38 
patients (44%), thyrotrophic insufficiency in 1 patient (1%) 
and corticotrophin insufficiency in 2 patients (2%). Like-
wise, long-term data on patients’ BMI (kg/m2) was miss-
ing for 13 patients (15%).
Operations were performed by three different neurosur-
geons, although mainly by one surgeon. In general, sur-
geons with higher levels of experience are associated with 
better outcomes in numerous studies [74, 75].
Values for individual adenoma size measurements and 
information about sphenoid sinus invasion in this patient 
cohort are missing, and allocation into groups (i.e., 
microadenoma and macroadenoma) doesn’t allow further 
subanalyses.
Conclusion
First-line surgery in patients with microprolactinomas or 
macroprolactinomas of Knosp grade 0 resulted in a good 
chance of non-dependency on DA therapy. However, in 
patients with prolactinomas Knosp grade 1, first-line 
surgery cannot be recommended, as adjuvant DA therapy 
after surgery is required in the majority over the long term.
Acknowledgements The assistance of Ms. Jeannie Wurz in editing the 
manuscript is greatly appreciated. We wish to thank Dr Markus Huber 
for statistical advice.
Author contributions LA contributed to study conception and design, 
statistical analysis and interpretation, drafting of the manuscript, criti-
cal revision and final approval of the article. EC contributed to study 
conception and design, data interpretation, critical revision and final 
approval of the article. JF contributed to the acquisition of data, and 
final approval of the article. RHA, MML, MEK, HRW, JB, LM, and 
RWS contributed to critical revision and final approval of the article.
Funding Open Access funding provided by Universität Bern. No fund-
ing was received for this publication.
Compliance with ethical standards 
Conflicts of interest This work has not been previously published and 
is not under consideration for publication anywhere else. The authors 
report no conflicts of interest concerning the materials or methods used 
in this study or the findings specified in this paper.
Ethical approval The Human Research Ethics Committee of Bern 
(Kantonale Ethikkommission KEK Bern, Bern, Switzerland) approved 
the study (KEK n° 10–10-2006 and 8–11-2006) and informed consent 
was obtained. The study was performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later 
amendments.
Informed consent Informed consent was obtained.
Data sharing statement The authors agree to share data upon request.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Colao A, Di Sarno A, Guerra E et al (2007) Predictors of remis-
sion of hyperprolactinaemia after long-term withdrawal of caber-
goline therapy. Clin Endocrinol 67:426–433. https:// doi. org/ 10. 
1111/j. 1365- 2265. 2007. 02905.x
 2. Kars M, Souverein PC, Herings RM et al (2009) Estimated age- 
and sex-specific incidence and prevalence of dopamine agonist-
treated hyperprolactinemia. J Clin Endocrinol Metab 94:2729–
2734. https:// doi. org/ 10. 1210/ jc. 2009- 0177
Journal of Endocrinological Investigation 
1 3
 3. Levy A. Pituitary disease: presentation, diagnosis, and manage-
ment. J Neurol Neurosurg Psychiatry 2004; 75 Suppl 3: iii47–52 
DOI: https:// doi. org/ 10. 1136/ jnnp. 2004. 045740
 4. Andereggen L, Mono ML, Kellner-Weldon F et al (2017) Cluster 
headache and macroprolactinoma: case report of a rare, but poten-
tial important causality. J Clin Neurosci 40:62–64. https:// doi. org/ 
10. 1016/j. jocn. 2017. 01. 028
 5. Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of trans-
sphenoidal surgery in prolactinomas: improvement of hormonal 
control in dopamine agonist-resistant patients. Euro J Endocrinol 
/ Euro Federation Endocrine Soc 166:779–786. https:// doi. org/ 10. 
1530/ EJE- 11- 1000
 6. Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactino-
mas. J Neurosurg 114:1369–1379. https:// doi. org/ 10. 3171/ 2010. 
11. JNS10 1369
 7. Ma Q, Su J, Li Y et al (2018) The chance of permanent cure for 
micro- and macroprolactinomas, medication or surgery? A sys-
tematic review and meta-analysis. Front Endocrinol (Lausanne) 
9:636. https:// doi. org/ 10. 3389/ fendo. 2018. 00636
 8. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F et al. 
Surgery as a viable alternative first-line treatment for prolactinoma 
patients. A systematic review and meta-analysis. The Journal of 
clinical endocrinology and metabolism 2019: DOI: https:// doi. 
org/ 10. 1210/ clinem/ dgz144
 9. Ogiwara T, Horiuchi T, Nagm A et al (2017) Significance of sur-
gical management for cystic prolactinoma. Pituitary 20:225–230. 
https:// doi. org/ 10. 1007/ s11102- 016- 0766-6
 10. Donoho DA, Laws ER Jr (2019) The role of surgery in the man-
agement of prolactinomas. Neurosurg Clin N Am 30:509–514. 
https:// doi. org/ 10. 1016/j. nec. 2019. 05. 010
 11. Vasilev V, Daly AF, Vroonen L et al (2011) Resistant prolacti-
nomas. J Endocrinol Invest 34:312–316. https:// doi. org/ 10. 3275/ 
760410. 1007/ BF033 47092
 12. Song YJ, Chen MT, Lian W et al (2017) Surgical treatment for 
male prolactinoma: a retrospective study of 184 cases. Medicine 
(Baltimore) 96:e5833. https:// doi. org/ 10. 1097/ MD. 00000 00000 
005833
 13. Casanueva FF, Molitch ME, Schlechte JA et al (2006) Guidelines 
of the pituitary society for the diagnosis and management of prol-
actinomas. Clin Endocrinol 65:265–273. https:// doi. org/ 10. 1111/j. 
1365- 2265. 2006. 02562.x
 14. Dekkers OM, Lagro J, Burman P et al (2010) Recurrence of 
hyperprolactinemia after withdrawal of dopamine agonists: 
systematic review and meta-analysis. J Clin Endocrinol Metab 
95:43–51. https:// doi. org/ 10. 1210/ jc. 2009- 1238
 15. Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treat-
ment of hyperprolactinemia: a study in 455 patients. J Clin Endo-
crinol Metab 84:2518–2522. https:// doi. org/ 10. 1210/ jcem. 84.7. 
5810
 16. Webster J, Piscitelli G, Polli A et al. A comparison of cabergoline 
and bromocriptine in the treatment of hyperprolactinemic amenor-
rhea. Cabergoline Comparative Study Group. The New England 
journal of medicine 1994; 331: 904–909 DOI: https:// doi. org/ 10. 
1056/ NEJM1 99410 06331 1403
 17. Herring N, Szmigielski C, Becher H et al (2009) Valvular heart 
disease and the use of cabergoline for the treatment of prolac-
tinoma. Clin Endocrinol 70:104–108. https:// doi. org/ 10. 1111/j. 
1365- 2265. 2008. 03458.x
 18. Zanettini R, Antonini A, Gatto G et al (2007) Valvular heart dis-
ease and the use of dopamine agonists for Parkinson’s disease. N 
Engl J Med 356:39–46. https:// doi. org/ 10. 1056/ NEJMo a0548 30
 19. Stiles CE, Tetteh-Wayoe ET, Bestwick J et al. A meta-analysis 
of the prevalence of cardiac valvulopathy in hyperprolactinemic 
patients treated with Cabergoline. The Journal of clinical endo-
crinology and metabolism 2018: DOI: https:// doi. org/ 10. 1210/ jc. 
2018- 01071
 20. Stiles CE, Lloyd G, Bhattacharyya S et al (2021) Incidence of 
cabergoline-associated valvulopathy in primary care patients with 
prolactinoma using hard cardiac endpoints. J Clin Endocrinol 
Metab 106:e711–e720. https:// doi. org/ 10. 1210/ clinem/ dgaa8 82
 21. Moore TJ, Glenmullen J, Mattison DR (2014) Reports of patho-
logical gambling, hypersexuality, and compulsive shopping asso-
ciated with dopamine receptor agonist drugs. JAMA Intern Med 
174:1930–1933. https:// doi. org/ 10. 1001/ jamai ntern med. 2014. 
5262
 22. Weiss HD, Pontone GM (2014) Dopamine receptor agonist drugs 
and impulse control disorders. JAMA Intern Med 174:1935–1937. 
https:// doi. org/ 10. 1001/ jamai ntern med. 2014. 4097
 23. Bancos I, Nannenga MR, Bostwick JM et al (2014) Impulse con-
trol disorders in patients with dopamine agonist-treated prolac-
tinomas and nonfunctioning pituitary adenomas: a case-control 
study. Clin Endocrinol 80:863–868. https:// doi. org/ 10. 1111/ cen. 
12375
 24. Ioachimescu AG, Fleseriu M, Hoffman AR et al (2019) Psycho-
logical effects of dopamine agonist treatment in patients with 
hyperprolactinemia and prolactin-secreting adenomas. Euro J 
Endocrinol / Euro Federation Endocrine Soc 180:31–40. https:// 
doi. org/ 10. 1530/ EJE- 18- 0682
 25. Andereggen L, Frey J, Christ E. Long-term IGF-1 monitoring 
in prolactinoma patients treated with cabergoline might not 
be indicated. Endocrine 2020: DOI: https:// doi. org/ 10. 1007/ 
s12020- 020- 02557-1
 26. Castinetti F, Albarel F, Amodru V et al (2021) The risks of 
medical treatment of prolactinoma. Ann Endocrinol 82:15–19. 
https:// doi. org/ 10. 1016/j. ando. 2020. 12. 008
 27. Tampourlou M, Trifanescu R, Paluzzi A et al (2016) THERAPY 
OF ENDOCRINE DISEASE: Surgery in microprolactinomas: 
effectiveness and risks based on contemporary literature. Euro 
J Endocrinol / Euro Federation Endocrine Soc 175:R89-96. 
https:// doi. org/ 10. 1530/ EJE- 16- 0087
 28. Babey M, Sahli R, Vajtai I et al (2011) Pituitary surgery for 
small prolactinomas as an alternative to treatment with dopa-
mine agonists. Pituitary 14:222–230. https:// doi. org/ 10. 1007/ 
s11102- 010- 0283-y
 29. Micko A, Vila G, Hoftberger R et al (2019) Endoscopic trans-
sphenoidal surgery of microprolactinomas: a reappraisal of cure 
rate based on radiological criteria. Neurosurgery 85:508–515. 
https:// doi. org/ 10. 1093/ neuros/ nyy385
 30. Andereggen L, Frey J, Andres RH et al (2017) Long-term fol-
low-up of primary medical versus surgical treatment of prolac-
tinomas in men: effects on hyperprolactinemia, hypogonadism, 
and bone health. World Neurosurg 97:595–602. https:// doi. org/ 
10. 1016/j. wneu. 2016. 10. 059
 31. Andereggen L, Frey J, Andres RH et al. 10-year follow-up study 
comparing primary medical vs. surgical therapy in women with 
prolactinomas. Endocrine 2017; 55: 223–230 DOI: https:// doi. 
org/ 10. 1007/ s12020- 016- 1115-2
 32. Kepenekian L, Cebula H, Castinetti F et al (2016) Long-term 
outcome of macroprolactinomas. Ann Endocrinol 77:641–648. 
https:// doi. org/ 10. 1016/j. ando. 2016. 07. 004
 33. Green AI, Sherlock M, Stewart PM et al (2014) Extensive expe-
rience in the management of macroprolactinomas. Clin Endo-
crinol 81:85–92. https:// doi. org/ 10. 1111/ cen. 12418
 34. Andereggen L, Frey J, Andres RH et al (2021) Persistent bone 
impairment despite long-term control of hyperprolactinemia 
and hypogonadism in men and women with prolactinomas. Sci 
Rep 11:5122. https:// doi. org/ 10. 1038/ s41598- 021- 84606-x
 35. Karavitaki N, Thanabalasingham G, Shore HC et al (2006) Do 
the limits of serum prolactin in disconnection hyperprolacti-
naemia need re-definition? A study of 226 patients with histo-
logically verified non-functioning pituitary macroadenoma. Clin 
 Journal of Endocrinological Investigation
1 3
Endocrinol 65:524–529. https:// doi. org/ 10. 1111/j. 1365- 2265. 
2006. 02627.x
 36. Cattaneo F, Kappeler D, Muller B. Macroprolactinaemia, the 
major unknown in the differential diagnosis of hyperprolactinae-
mia. Swiss medical weekly 2001; 131: 122-126 DOI: 2001/09/
smw-06127
 37. Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis 
and treatment of hyperprolactinemia: an endocrine society clinical 
practice guideline. J Clin Endocrinol Metab 96:273–288. https:// 
doi. org/ 10. 1210/ jc. 2010- 1692
 38. Andereggen L, Gralla J, Schroth G et al (2021) Influence of infe-
rior petrosal sinus drainage symmetry on detection of adenomas 
in Cushing’s syndrome. J Neuroradiol 48:10–15. https:// doi. org/ 
10. 1016/j. neurad. 2019. 05. 004
 39. Andereggen L, Schroth G, Gralla J et al (2012) Selective inferior 
petrosal sinus sampling without venous outflow diversion in the 
detection of a pituitary adenoma in Cushing’s syndrome. Neurora-
diology 54:495–503. https:// doi. org/ 10. 1007/ s00234- 011- 0915-6
 40. Knosp E, Steiner E, Kitz K et al. Pituitary adenomas with inva-
sion of the cavernous sinus space: a magnetic resonance imag-
ing classification compared with surgical findings. Neurosur-
gery 1993; 33: 610–617; discussion 617–618 DOI: https:// doi. 
org/ 10. 1227/ 00006 123- 19931 0000- 00008
 41. Micko AS, Wohrer A, Wolfsberger S et al (2015) Invasion of 
the cavernous sinus space in pituitary adenomas: endoscopic 
verification and its correlation with an MRI-based classifica-
tion. J Neurosurg 122:803–811. https:// doi. org/ 10. 3171/ 2014. 
12. JNS14 1083
 42. Lopes MBS (2017) The 2017 World Health Organization 
classification of tumors of the pituitary gland: a summary. 
Acta Neuropathol 134:521–535. https:// doi. org/ 10. 1007/ 
s00401- 017- 1769-8
 43. Kruljac I, Kirigin LS, Strinovic M et  al (2015) Treatment 
of prolactinomas in low-income countries. Int J Endocrinol 
2015:697065. https:// doi. org/ 10. 1155/ 2015/ 697065
 44. Seiler RW, Mariani L (2000) Sellar reconstruction with resorb-
able vicryl patches, gelatin foam, and fibrin glue in transsphenoi-
dal surgery: a 10-year experience with 376 patients. J Neurosurg 
93:762–765. https:// doi. org/ 10. 3171/ jns. 2000. 93.5. 0762
 45. Arduc A, Gokay F, Isik S et al (2015) Retrospective comparison 
of cabergoline and bromocriptine effects in hyperprolactinemia: a 
single center experience. J Endocrinol Invest 38:447–453. https:// 
doi. org/ 10. 1007/ s40618- 014- 0212-4
 46. Wass JA (2006) When to discontinue treatment of prolactinoma? 
Nat Clin Pract Endocrinol Metab 2:298–299. https:// doi. org/ 10. 
1038/ ncpen dmet0 162
 47. Colao A, Di Sarno A, Cappabianca P et al (2003) Withdrawal of 
long-term cabergoline therapy for tumoral and nontumoral hyper-
prolactinemia. N Engl J Med 349:2023–2033. https:// doi. org/ 10. 
1056/ NEJMo a0226 57
 48. Eroukhmanoff J, Tejedor I, Potorac I et al (2017) MRI follow-up 
is unnecessary in patients with macroprolactinomas and long-term 
normal prolactin levels on dopamine agonist treatment. Euro J 
Endocrinol / Euro Federation Endocrine Soc 176:323–328. https:// 
doi. org/ 10. 1530/ EJE- 16- 0897
 49. Varlamov EV, Hinojosa-Amaya JM, Fleseriu M. Magnetic res-
onance imaging inthe management of prolactinomas; a review 
of the evidence. Pituitary 2019: DOI: https:// doi. org/ 10. 1007/ 
s11102- 019- 01001-6
 50. Molitch ME (2017) Diagnosis and treatment of pituitary adeno-
mas: a review. JAMA 317:516–524. https:// doi. org/ 10. 1001/ jama. 
2016. 19699
 51. Demartini B, Ricciardi L, Ward A et al (2014) Dopamine agonist 
withdrawal syndrome (DAWS) in a patient with a microprolacti-
noma. J Neurol Neurosurg Psychiatry 85:471. https:// doi. org/ 10. 
1136/ jnnp- 2013- 306043
 52. Honegger J, Nasi-Kordhishti I, Aboutaha N et al (2020) Surgery 
for prolactinomas: a better choice? Pituitary 23:45–51. https:// doi. 
org/ 10. 1007/ s11102- 019- 01016-z
 53. Landolt AM, Keller PJ, Froesch ER et al (1982) Bromocriptine: 
Does it jeopardise the result of later surgery for prolactinomas? 
Lancet 2:657–658. https:// doi. org/ 10. 1016/ s0140- 6736(82) 
92756-8
 54. Menucci M, Quinones-Hinojosa A, Burger P et  al (2011) 
Effect of dopaminergic drug treatment on surgical findings in 
prolactinomas. Pituitary 14:68–74. https:// doi. org/ 10. 1007/ 
s11102- 010- 0261-4
 55. Donegan D, Atkinson JL, Jentoft M et al (2017) Surgical out-
comes of prolactinomas in recent era: results of a heterogenous 
group. Endocr Pract 23:37–45. https:// doi. org/ 10. 4158/ EP161 446. 
OR
 56. Landolt AM, Osterwalder V (1984) Perivascular fibrosis in pro-
lactinomas: is it increased by bromocriptine? J Clin Endocrinol 
Metab 58:1179–1183. https:// doi. org/ 10. 1210/ jcem- 58-6- 1179
 57. Button KS, Ioannidis JP, Mokrysz C et al (2013) Power failure: 
why small sample size undermines the reliability of neuroscience. 
Nat Rev Neurosci 14:365–376. https:// doi. org/ 10. 1038/ nrn34 75
 58. Lobatto DJ, Steffens ANV, Zamanipoor Najafabadi AH et al 
(2018) Work disability and its determinants in patients with pitui-
tary tumor-related disease. Pituitary 21:593–604. https:// doi. org/ 
10. 1007/ s11102- 018- 0913-3
 59. Uvelius E, Castelo N, Kahlon B et al (2017) Quality of life and 
work capacity are unrelated to approach or complications after 
pituitary surgery. World neurosurgery 108:24–32. https:// doi. org/ 
10. 1016/j. wneu. 2017. 08. 087
 60. Vega-Beyhart A, Enriquez-Estrada VM, Bello-Chavolla OY et al 
(2019) Quality of life is significantly impaired in both secretory 
and non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 
90:457–467. https:// doi. org/ 10. 1111/ cen. 13915
 61. van der Meulen M, Zamanipoor Najafabadi AH, Lobatto DJ et al 
(2021) Healthcare utilization and costs among prolactinoma 
patients: a cross-sectional study and analysis of determinants. 
Pituitary 24:79–95. https:// doi. org/ 10. 1007/ s11102- 020- 01089-1
 62. Jethwa PR, Patel TD, Hajart AF et al (2016) Cost-effectiveness 
analysis of microscopic and endoscopic transsphenoidal surgery 
versus medical therapy in the management of microprolactinoma 
in the United States. World neurosurgery 87:65–76. https:// doi. 
org/ 10. 1016/j. wneu. 2015. 10. 090
 63. Tabaee A, Anand VK, Barron Y et al (2009) Endoscopic pitui-
tary surgery: a systematic review and meta-analysis. J Neurosurg 
111:545–554. https:// doi. org/ 10. 3171/ 2007. 12. 17635
 64. Zatelli MC, Ambrosio MR, Bondanelli M et al (2007) Control 
of pituitary adenoma cell proliferation by somatostatin analogs, 
dopamine agonists and novel chimeric compounds. Euro J Endo-
crinol / Euro Federation Endocrine Soc 156(Suppl 1):S29–S35. 
https:// doi. org/ 10. 1530/ eje.1. 02352
 65. Lafeber M, Stades AM, Valk GD et al (2010) Absence of major 
fibrotic adverse events in hyperprolactinemic patients treated with 
cabergoline. Euro J Endocrinol / Euro Federation Endocrine Soc 
162:667–675. https:// doi. org/ 10. 1530/ EJE- 09- 0989
 66. Drake WM, Stiles CE, Howlett TA et al (2014) A cross-sectional 
study of the prevalence of cardiac valvular abnormalities in hyper-
prolactinemic patients treated with ergot-derived dopamine ago-
nists. J Clin Endocrinol Metab 99:90–96. https:// doi. org/ 10. 1210/ 
jc. 2013- 2254
 67. Han YL, Chen DM, Zhang C et al (2018) Retrospective analysis 
of 52 patients with prolactinomas following endoscopic endonasal 
transsphenoidal surgery. Medicine (Baltimore) 97:e13198. https:// 
doi. org/ 10. 1097/ MD. 00000 00000 013198
 68. Ono M, Miki N, Kawamata T et al (2008) Prospective study of 
high-dose cabergoline treatment of prolactinomas in 150 patients. 
Journal of Endocrinological Investigation 
1 3
J Clin Endocrinol Metab 93:4721–4727. https:// doi. org/ 10. 1210/ 
jc. 2007- 2758
 69. Schlechte JA (2007) Long-term management of prolactinomas. J 
Clin Endocrinol Metab 92:2861–2865. https:// doi. org/ 10. 1210/ jc. 
2007- 0836
 70. Sosa-Eroza E, Espinosa E, Ramirez-Renteria C et al (2018) Treat-
ment of multiresistant prolactinomas with a combination of caber-
goline and octreotide LAR. Endocrine 61:343–348. https:// doi. 
org/ 10. 1007/ s12020- 018- 1638-9
 71. Kwancharoen R, Auriemma RS, Yenokyan G et al (2014) Second 
attempt to withdraw cabergoline in prolactinomas: a pilot study. 
Pituitary 17:451–456. https:// doi. org/ 10. 1007/ s11102- 013- 0525-x
 72. Xia MY, Lou XH, Lin SJ et al (2018) Optimal timing of dopamine 
agonist withdrawal in patients with hyperprolactinemia: a system-
atic review and meta-analysis. Endocrine 59:50–61. https:// doi. 
org/ 10. 1007/ s12020- 017- 1444-9
 73. Sala E, Bellaviti Buttoni P, Malchiodi E et al (2016) Recurrence 
of hyperprolactinemia following dopamine agonist withdrawal 
and possible predictive factors of recurrence in prolactinomas. 
J Endocrinol Invest 39:1377–1382. https:// doi. org/ 10. 1007/ 
s40618- 016- 0483-z
 74. Bunevicius A, Laws ER, Vance ML et  al (2019) Surgi-
cal and radiosurgical treatment strategies for Cushing’s dis-
ease. J Neurooncol 145:403–413. https:// doi. org/ 10. 1007/ 
s11060- 019- 03325-6
 75. Honegger J, Grimm F (2018) The experience with transsphenoidal 
surgery and its importance to outcomes. Pituitary 21:545–555. 
https:// doi. org/ 10. 1007/ s11102- 018- 0904-4
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
